Brief: Poxel End-Dec Total Cash And Cash Equivalents At EUR 40.2 Million

Poxel SA

12/02/2021 06:58

Feb 12 (Reuters) - Poxel SA  POXEL.PA :
    * FY REVENUE 6.7 MILLION EUR VERSUS 26.6 MILLION EUR YEAR
AGO
    * AS OF DECEMBER 31, 2020, CASH AND CASH EQUIVALENTS WERE
EUR 40.2
MILLION (USD 49.4 MILLION)
    * IMEGLIMIN JAPANESE NEW DRUG APPLICATION (J-NDA) UNDER
REVIEW
FOLLOWING SUBMISSION BY POXEL'S PARTNER SUMITOMO DAINIPPON
PHARMA IN JULY 2020
    * NEW RESULTS FROM PXL770 PHASE 2A STAMP-NAFLD TRIAL FOR
TREATMENT
OF NASH SHOWED CONSISTENTLY GREATER RESPONSE IN HIGH-RISK
PATIENTS WITH COEXISTING TYPE 2 DIABETES (T2DM)
    * POXEL ANNOUNCED PLANS TO CONDUCT A 52-WEEK PHASE 2B TRIAL
EVALUATING UP TO TWO DOSES OF PXL770 IN APPROXIMATELY 100
PATIENTS PER STUDY ARM WITH BIOPSY-PROVEN NASH AND PRE-DIABETES
OR T2DM
    * AS OF DECEMBER 31, 2020, TOTAL CASH AND CASH EQUIVALENTS
WERE
EUR 40.2 MILLION (USD 49.4 MILLION)

Source text for Eikon:  ID:nBw5Ps1Hya 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))